Not just ticking boxes! Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA What’s new? Providing a stem so criteria will be applied only if w/SpA dx, not just imaging MRI:active inflamm + structural lesions Some SpA features omitted @RheumNow #EULAR2026 https://t.co/NCV0EFvjYa

• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1
• https://x.com/RHEUMarampa/status/2062900936402485307/photo/1

#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5

• https://x.com/Yuz6Yusof/status/2062849640374890515/photo/1

In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP. At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+ POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr

• https://x.com/RHEUMarampa/status/2062829262353125624/photo/1

Double targeted therapy in refractory SpA/PsA. 76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics. Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit. ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX

• https://x.com/synovialjoints/status/2062799915672031405/photo/1

10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA): 81.6% (40/49) were in clinical remission 15 pts on drug-free remission 21 pts w/remission on meds still on GOL, no unSSAEs Early aggressive tx is key! AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt

• https://x.com/RHEUMarampa/status/2062797311827210457/photo/1
• https://x.com/RHEUMarampa/status/2062797311827210457/photo/1

#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At

• https://x.com/Yuz6Yusof/status/2062828345583186416/photo/1

🔥 TOGETHER-PsA (OP069) #EULAR2026 #EULARbest Ixekizumab + Tirzepatide vs IXE alone in PsA with obesity/overweight: ✅ Primary endpoint (ACR50 + ≥10% wt loss at W36): 31.7% vs. 0.8% (p<0.001) ✅ ACR50: 33.5% vs. 20.4% ✅ MDA: 26.3% vs. 15.3% (p=0.026) @rheumnow @DrLauraCoates https://t.co/6wh3S6khXw

• https://x.com/Nellziade/status/2062565805594755234/photo/1

🧬 Does spine vs knee enthesis differ immunologically? Translational scRNAseq study: YES! Spine produces more IL-23 but shows attenuated IL-17 response vs knee #POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ

• https://x.com/Nellziade/status/2062550503393828865/photo/1

🎗️ Do targeted therapies raise cancer risk in SpA? French nationwide cohort (n=56,591): NO In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological. #OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX

• https://x.com/Nellziade/status/2062545816187699690/photo/1

💊 After TNFi failure in axSpA, switch to IL-17Ai or cycle TNFi? ROC-SpA (Phase 4 RCT, n=300): NO difference: ASAS40 15.2% vs 14.5% at week 24 #OP0235 #EULAR2026 @RheumNow https://t.co/45gisWiuoM

• https://x.com/Nellziade/status/2062544752814289277/photo/1

💉 Does bimekizumab work in real-world PsA? YES - EuroSpA: 76% retention at 6months 46% DAPSA LDA in 787pts across 12 registries #OP0185 #EULAR2026 @RheumNow https://t.co/TXS3r9mZXB

• https://x.com/Nellziade/status/2062543554623291769/photo/1

🧲 Does GUS+GOL combo beat GUS alone on MRI in PsA? YES for joints - AFFINITY Phase 2a RCT: greater MRI inflammation reduction in 91pts #OP0186 #EULAR2026 @RheumNow https://t.co/9eIS6lh7WN

• https://x.com/Nellziade/status/2062542859106910588/photo/1